Outer membrane vesicles (OMVs) are released spontaneously during growth by many Gram‐
negative bacteria. They present a range of surface antigens in a native conformation and …

Vaccine development, which began with Edward Jenner's observations in the late 18th
century, has entered its 4th century. From its beginnings, with the use of whole organisms …

Background Meningococcal serogroup B disease disproportionately affects infants. We
assessed lot-to-lot consistency, safety and immunogenicity, and the effect of concomitant …

Background Effective glycoconjugate vaccines against Neisseria meningitidis serogroups A,
C, W-135, and Y have been developed, but serogroup B remains a major cause of severe …

No broadly effective vaccines are available for prevention of group B meningococcal
disease, which accounts for> 50% of all cases. The group B capsule is an autoantigen and …

Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human
clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein …

Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans
and can cause devastating invasive disease. Although capsular polysaccharide-based …

The Global Meningococcal Initiative (GMI) is composed of an international group of
scientists, clinicians and public health officials with expertise in meningococcal immunology …

Certain pathogens recruit host complement inhibitors such as factor H (fH) to evade the
immune system. Microbial complement inhibitor-binding molecules can be promising …

Neisseria meningitidis is responsible for the seasonal burden and recurrent epidemics of
meningitis in an area of sub-Saharan Africa known as the meningitis belt. Historically, the …